{"id":853695,"date":"2025-05-22T08:17:16","date_gmt":"2025-05-22T12:17:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/"},"modified":"2025-05-22T08:17:16","modified_gmt":"2025-05-22T12:17:16","slug":"evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/","title":{"rendered":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01"},"content":{"rendered":"<div class=\"mw_release\">\n<p \/>\n<ul>\n<li>\n          <b>Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>Will provide insights into the durability of immune and clinical responses up to three years<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>Extension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of care<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>Minimal costs are associated with the extension as clinical sites are already running and the vaccines are produced<\/b>\n        <\/li>\n<li style=\"text-align: justify\" data-mce-style=\"text-align: justify;\">\n          <b>The trial remains on track for two-year data readout in the second half of 2025<\/b><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, May 22, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).<\/p>\n<p align=\"justify\">The extension will further explore the full potential of EVX-01 as a possible new and innovative treatment of advanced melanoma, particularly its long-term clinical and immune benefits. The trial extension involves minimal cost as trial sites are running and the vaccine product has already been produced.<\/p>\n<p align=\"justify\">Having completed the initial two-year treatment, the first patient in the extension of the trial has now received the first additional dose of EVX-01. Patients entering the one-year extension of the trial will in total receive two additional EVX-01 doses as monotherapy.<\/p>\n<p align=\"justify\">In the first two years of the trial, EVX-01 was administered in combination with standard anti-PD-1 therapy (checkpoint inhibitors). With checkpoint inhibitor treatment restricted to a two-year duration, the extension phase provides an opportunity to evaluate the benefits of EVX-01 monotherapy. This could position EVX-01 as a potential standalone treatment for advanced melanoma.<\/p>\n<p align=\"justify\">\u201cExtending the trial allows us to explore EVX-01\u2019s potential beyond its combination use with checkpoint inhibitors. By studying EVX-01 as a monotherapy, we aim to assess the independent effects of EVX-01, including its induced immune response and clinical outcome. Given that checkpoint inhibitor therapy is not approved beyond two years of treatment, this additional EVX-01 treatment option could offer a meaningful option for patients\u201d, says Birgitte R\u00f8n\u00f8, Chief Scientific Officer of Evaxion.<\/p>\n<p align=\"justify\">EVX-01 is designed with Evaxion\u2019s AI-Immunology\u2122 platform and tailored to target the unique tumor profile and immune characteristics of each individual patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">The phase 2 trial investigates EVX-01 in combination with MSD\u2019s (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p align=\"justify\">\n        <b>Convincing one-year phase 2 data<\/b><br \/>\n        <br \/>Initially planned to run for two years, the trial remains on track to yield two-year data for presentation in the second half of 2025. Convincing interim one-year data from the trial was presented at the European Society for Medical Oncology (ESMO) Congress in September 2024. Data demonstrated a 69% Overall Response Rate, reduction in tumor target lesions in 15 out of 16 patients, and a positive correlation between the AI-Immunology\u2122 platform predictions and immune responses induced by the individual neoantigens in the EVX-01 vaccine (p=0.00013).<\/p>\n<p align=\"justify\">Further, 80% of EVX-01\u2019s vaccine targets triggered a targeted immune response, as presented at American Association for Cancer Research (AACR) Annual Meeting in April 2025. This number compares very favorably to what is seen with other approaches.<\/p>\n<p align=\"justify\">\n        <b>About EVX-01<\/b><br \/>\n        <br \/>EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion\u2019s lead clinical asset.<\/p>\n<p align=\"justify\">EVX-01 is a personalized therapy designed with our AI-Immunology\u2122 platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">In the completed phase 1\/2a clinical trial (NCT03715985), assessing EVX-01 in combination with a PD-1 inhibitor, eight of twelve metastatic melanoma patients (67%) had objective clinical responses, with two complete and six partial responses.<\/p>\n<p align=\"justify\">In addition, vaccine-induced T cells were detected in all patients and a significant correlation between clinical response and the AI-Immunology\u2122 predictions was observed, underlining the predictive power of the platform.<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uh0x7UpLbweMcFsv38PSAUqvpWlTL2N7b0rA9QxdBIatIcRxujVeP7Pna2PJqPZfVOGmc2ttWwCHCnUbbu4cjJVOGKFsPFVVmvOyC4qtRYQ=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"mailto:mak@evaxion.ai\">mak@evaxion.ai<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion A\/S is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iaxcJjn3jUZCAX4GjNJH2GEOniOmn5wG5fa-fQhGneRQ1RKV2q4JkR3HKs3Vfp4i6sBuHDrgofGm-pPWOV9CpqQ7YMBrQpNNY8lFyYFb0c8=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"https:\/\/www.evaxion.ai\/\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zmCrH0GZwNgOokQMz_c7O0NJSXZ94qqdMQQcLDMeTYPawtElZ-j514hBiJHlQ9DnyMU_Tm_HY2L-FHzyEpN7ZeyR8BV2JULqW71QPFHpJFOd1b9erHQXkcG6zPlr5xtVs7Im5OxxjQBUPHDbrLDdtxorjmp5WnMnrw-IzaP3ABXAZbzGAfBhHTjKkdjqxFthg3pZ9-oVxuDWjBwqoA-LfvHtVpoH96c7iTF3qj3pCtE=\" rel=\"nofollow noopener\" target=\"_blank\" data-mce-href=\"https:\/\/www.globenewswire.com\/Tracker?data=3eX-yULjXHj_fAO4jPRASPaehYEVHM4NmXNAs_0lw5UK0DHjLXk6aKS6LI4PyMob9UvuFpZpGQrWa4b_6WQY1A==\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YjI4MzdhMGUtZTdjZi00YmUzLTgxMmQtYzI1ZDFmYWYyOTcyLTEyNjM2NDAtMjAyNS0wNS0yMi1lbg==\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of care Minimal costs are associated with the extension as clinical sites are already running and the vaccines are produced The trial remains on track for two-year data readout in the second half of 2025 COPENHAGEN, Denmark, May 22, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has dosed the first patient in its one-year extension of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-853695","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of care Minimal costs are associated with the extension as clinical sites are already running and the vaccines are produced The trial remains on track for two-year data readout in the second half of 2025 COPENHAGEN, Denmark, May 22, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has dosed the first patient in its one-year extension of the &hellip; Continue reading &quot;Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-22T12:17:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01\",\"datePublished\":\"2025-05-22T12:17:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/\"},\"wordCount\":1135,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/\",\"name\":\"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\",\"datePublished\":\"2025-05-22T12:17:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk","og_description":"Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of care Minimal costs are associated with the extension as clinical sites are already running and the vaccines are produced The trial remains on track for two-year data readout in the second half of 2025 COPENHAGEN, Denmark, May 22, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has dosed the first patient in its one-year extension of the &hellip; Continue reading \"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-22T12:17:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01","datePublished":"2025-05-22T12:17:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/"},"wordCount":1135,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/","name":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==","datePublished":"2025-05-22T12:17:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA5ODI5NyM0MDIxNDYxODgjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-doses-first-patient-in-extension-of-phase-2-trial-exploring-the-full-potential-of-ai-designed-personalized-cancer-vaccine-evx-01\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/853695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=853695"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/853695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=853695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=853695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=853695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}